ByHeart Acquires Perrigo Formula Business for $175M
The purchase consolidates key production capacity and changes the competitive landscape for infant nutrition suppliers.
Updated on Oct. 29, 2026 in Healthcare
Live Poll
Should large companies be allowed to consolidate the infant formula market?
Executives led by ByHeart have reached a definitive agreement to purchase Perrigo Co.'s infant formula business. The deal, valued at up to $175 million, marks a significant consolidation shift within the specialized nutrition and consumer goods manufacturing sector.
Why it matters
For operators in the consumer goods space, this acquisition signals ongoing consolidation in a highly regulated market where supply chain stability remains a top priority. This movement allows the purchasing group to integrate established manufacturing capacity into their existing operations.
The acquisition of the infant formula business totals up to $175 million in an official filing. This deal consolidates a key production segment under new leadership to scale manufacturing capabilities.
The players
ByHeart
A developer and manufacturer of infant nutrition products focused on clinical-grade formula.
Perrigo Co.
A multinational consumer self-care and pharmaceutical manufacturer that produces store-brand health products.
Ron Belldegrun
An executive leader spearheading the purchasing entity for the infant formula business acquisition.
Mia Funt
An executive leader co-managing the acquisition of the Perrigo formula division.
The details
The purchase agreement allows ByHeart to acquire the assets and infrastructure of the Perrigo infant formula division. By integrating these facilities, the new ownership aims to streamline production cycles and address supply constraints inherent to the formula industry. Operators should monitor how the integration changes the competitive landscape for specialized nutrition shelf space.
Timeline
October 29, 2026: Perrigo announced the infant formula business sale.
Market Landscape
The acquisition follows broader industry shifts driven by the 2022 Infant Formula Crisis supply chain regulations, which have forced manufacturers to increase production capacity and facility redundancies. This move marks a strategic effort to consolidate specialized manufacturing under more agile management.
Operators in the consumer health supply chain should watch for shifts in contract manufacturing terms as leadership changes hands. Keep track of how this consolidation affects regional availability and potential pricing structures for shelf-stable infant nutrition.
The takeaway
This deal underscores the premium placed on domestic manufacturing infrastructure within the highly regulated nutrition sector. Owners should audit their own supply chain vulnerabilities and ensure they have diverse vendor agreements to mitigate risks during major industry transitions.
Further reading
For more on shifting standards and production trends, visit the Healthcare section.
Source note: This article includes information reported by Bloomberg Business.
Live Poll
Should large companies be allowed to consolidate the infant formula market?
